1. Volume 139, Issue 4, Pages 1207-1217.e3 (October 2010)
Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection 
Thomas Berg, Patrick Marcellin, Fabien Zoulim, Bernd Moller, Huy Trinh, Sing Chan, Emilio Suarez, Fabien Lavocat, Andrea Snow– Lampart, David Frederick, Jeff Sorbel, Katyna Borroto–Esoda, David Oldach, Franck Rousseau 
Gastroenterology 
Volume 139, Issue 4, Pages e3 (October 2010)
DOI: /j.gastro
Copyright © 2010 AGA Institute Terms and Conditions

2. Figure 1
Mean (95% confidence interval) HBV DNA (log10 copies/mL) by study visit (RAT analysis set) and initial treatment assignment.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

3. Figure 2
Percentage of patients with HBV DNA <400 copies/mL by study visit and initial treatment assignment (intent-to-treat: NC = F analysis). Patients who switched to open-label FTC/TDF after week 24 were included in the analysis as part of their original randomized treatment group.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

4. Figure 3
(A and B) Median change in HBV DNA by baseline ADV-R (A) or LAM-R (B) detected by population sequencing.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

5. Figure 4
(A and B) Median change in HBV DNA by baseline ADV-R (A) or LAM-R (B) detected by INNO-LiPA.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

6. Supplementary Figure 1 Disposition of study patients.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

7. Supplementary Figure 2
HBV DNA log10 copies/mL by study visit for patients randomized to blinded tenofovir disoproxil fumarate treatment who switched to open-label emtricitabine/tenofovir disoproxil fumarate treatment after week 24.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

8. Supplementary Figure 3
Percentage of patients with HBV DNA <400 copies/mL by adherence. High adherence was defined as ≥94%, and low adherence was defined as ≤68%. Patient adherence to study drug was measured by a count of pills returned at each postbaseline visit.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions